However, the detailed mechanisms that drive powerful antioxidant systems of DTP cancer cells are not clear, and existing available agents based on redox regulation, such as glutathione peroxidase 4 (GPX4) inhibitors, remain challenging to translate into therapeutic uses. This evidence concerns the gene GPX4 and cancer.